{"name":"Huons Co., Ltd.","slug":"huons-co-ltd","ticker":"","exchange":"","domain":"huons.com","description":"","hq":"Ansan","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"HE 10","genericName":"HE 10","slug":"he-10","indication":"Other","status":"phase_3"},{"name":"Amosartan","genericName":"Amosartan","slug":"amosartan","indication":"Other","status":"phase_2"},{"name":"Besylsartan","genericName":"Besylsartan","slug":"besylsartan","indication":"Other","status":"phase_1"},{"name":"HU00701","genericName":"HU00701","slug":"hu00701","indication":"Other","status":"phase_2"},{"name":"HUC3-637","genericName":"HUC3-637","slug":"huc3-637","indication":"Other","status":"phase_3"},{"name":"HUC3-637-R","genericName":"HUC3-637-R","slug":"huc3-637-r","indication":"Other","status":"phase_3"},{"name":"Humia inj.","genericName":"Humia inj.","slug":"humia-inj","indication":"Adjuvant to enhance subcutaneous or intradermal administration of other drugs (phase 3 development)","status":"phase_3"},{"name":"Hutox Inj","genericName":"Hutox Inj","slug":"hutox-inj","indication":"Facial wrinkles and dynamic expression lines (aesthetic indication)","status":"phase_3"},{"name":"Moisview","genericName":"Moisview","slug":"moisview","indication":"Other","status":"phase_3"},{"name":"Restasis","genericName":"Restasis","slug":"restasis","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"neuroscience","drugs":[{"name":"HA 0.3%","genericName":"HA 0.3%","slug":"ha-0-3","indication":"Dry eye syndrome or ocular surface disease (if ophthalmic formulation)","status":"phase_3"},{"name":"Hyalein Mini Eye Drops","genericName":"Hyalein Mini Eye Drops","slug":"hyalein-mini-eye-drops","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"phase_3"},{"name":"Moisview Eye drop","genericName":"Moisview Eye drop","slug":"moisview-eye-drop","indication":"Dry eye disease (keratoconjunctivitis sicca)","status":"phase_3"},{"name":"Restasis eye drop","genericName":"Restasis eye drop","slug":"restasis-eye-drop","indication":"Dry eye disease (keratoconjunctivitis sicca) to increase tear production","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"HU-014 Inj","genericName":"HU-014 Inj","slug":"hu-014-inj","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HU007","genericName":"HU007","slug":"hu007","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HU-014","genericName":"HU-014","slug":"hu-014","indication":"Metastatic non-small cell lung cancer","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Botox Inj","genericName":"Botox Inj","slug":"botox-inj","indication":"Cervical dystonia","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"High hyal Plus inj.","genericName":"High hyal Plus inj.","slug":"high-hyal-plus-inj","indication":"Osteoarthritis (likely knee or other joints)","status":"phase_3"}]}],"pipeline":[{"name":"HE 10","genericName":"HE 10","slug":"he-10","phase":"phase_3","mechanism":"HE 10 is a therapeutic agent in development by Huons Co., Ltd., currently in phase 3 clinical trials.","indications":[],"catalyst":""},{"name":"HU-014","genericName":"HU-014","slug":"hu-014","phase":"phase_3","mechanism":"HU-014 is a synthetic oligonucleotide that acts as a telomerase inhibitor.","indications":["Metastatic non-small cell lung cancer"],"catalyst":""},{"name":"Amosartan","genericName":"Amosartan","slug":"amosartan","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Besylsartan","genericName":"Besylsartan","slug":"besylsartan","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Botox Inj","genericName":"Botox Inj","slug":"botox-inj","phase":"phase_3","mechanism":"Botox (botulinum toxin type A) blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Cervical dystonia","Blepharospasm","Hemifacial spasm","Chronic migraine","Overactive bladder"],"catalyst":""},{"name":"HA 0.3%","genericName":"HA 0.3%","slug":"ha-0-3","phase":"phase_3","mechanism":"HA 0.3% is a hyaluronic acid-based topical or injectable formulation that provides hydration, lubrication, and tissue support through its viscoelastic properties.","indications":["Dry eye syndrome or ocular surface disease (if ophthalmic formulation)","Wound healing or skin hydration (if dermatologic formulation)"],"catalyst":""},{"name":"HU-014 Inj","genericName":"HU-014 Inj","slug":"hu-014-inj","phase":"phase_3","mechanism":"HU-014 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HU007","genericName":"HU007","slug":"hu007","phase":"phase_3","mechanism":"HU007 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HU00701","genericName":"HU00701","slug":"hu00701","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HUC3-637","genericName":"HUC3-637","slug":"huc3-637","phase":"phase_3","mechanism":"HUC3-637 is an investigational drug with unknown mechanism of action.","indications":[],"catalyst":""},{"name":"HUC3-637-R","genericName":"HUC3-637-R","slug":"huc3-637-r","phase":"phase_3","mechanism":"HUC3-637-R's mechanism of action is currently unknown.","indications":[],"catalyst":""},{"name":"High hyal Plus inj.","genericName":"High hyal Plus inj.","slug":"high-hyal-plus-inj","phase":"phase_3","mechanism":"High hyal Plus is a hyaluronic acid-based injectable that provides viscoelastic supplementation and tissue hydration for joint or dermatological applications.","indications":["Osteoarthritis (likely knee or other joints)","Dermatological applications (skin hydration/rejuvenation)"],"catalyst":""},{"name":"Humia inj.","genericName":"Humia inj.","slug":"humia-inj","phase":"phase_3","mechanism":"Humia is a recombinant human hyaluronidase injection designed to enhance tissue permeability and facilitate drug distribution.","indications":["Adjuvant to enhance subcutaneous or intradermal administration of other drugs (phase 3 development)"],"catalyst":""},{"name":"Hutox Inj","genericName":"Hutox Inj","slug":"hutox-inj","phase":"phase_3","mechanism":"Hutox is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","indications":["Facial wrinkles and dynamic expression lines (aesthetic indication)","Muscle hyperactivity disorders (therapeutic indication)"],"catalyst":""},{"name":"Hyalein Mini Eye Drops","genericName":"Hyalein Mini Eye Drops","slug":"hyalein-mini-eye-drops","phase":"phase_3","mechanism":"Hyalein Mini Eye Drops is a hyaluronic acid-based lubricating eye drop that provides moisture and protection to the ocular surface.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"Moisview","genericName":"Moisview","slug":"moisview","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Moisview Eye drop","genericName":"Moisview Eye drop","slug":"moisview-eye-drop","phase":"phase_3","mechanism":"Moisview is an eye drop formulation designed to treat dry eye disease by providing ocular surface lubrication and potentially reducing inflammation.","indications":["Dry eye disease (keratoconjunctivitis sicca)"],"catalyst":""},{"name":"Restasis","genericName":"Restasis","slug":"restasis","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Restasis eye drop","genericName":"Restasis eye drop","slug":"restasis-eye-drop","phase":"phase_3","mechanism":"Restasis (cyclosporine) suppresses T-cell activation and reduces inflammatory cytokine production in the lacrimal glands and ocular surface to increase tear production.","indications":["Dry eye disease (keratoconjunctivitis sicca) to increase tear production"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaldOR1BjTFc5OTMxbGV3dUpmc3l2ZlFxUjU5ejdEcTVQVllKOEt2M2pSY2VUdVFtRlFVYXBpNFNLT0hXT1lYTFo3UmhqOVZzYTZkNE1jNEhiZEpnZFc0dE04dHpFSGZrWl9MSC1lX0Y1US1WSDYzQXdiVnFud0djTXBRbFBqbllvT0hWT2UzX3NLOUYyQ3JIX3c1TDBaelRaYzExRWhSWEhQQQ?oc=5","date":"2024-11-07","type":"deal","source":"Contract Pharma","summary":"Huons Acquires Stake in PanGen to Bolster Biopharma Business - Contract Pharma","headline":"Huons Acquires Stake in PanGen to Bolster Biopharma Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxONV92WHdqb3JxdFduRWtIb01RNWRtT2tSR19pNTBJdGc5VkUxRFhLT3J2ZG9XUEF6aFhJTGdFX0IxVDc3TjdKOU95OG50S3hhUENWbzU1ZVcyMGc2UHhwX2RwcjVLOXZRRlFaUFVBcHN6MThxVDNtb052NG9KelZMWWtQVEhBSlVuZF9Ed0pUUHdkVkw4STNqSU03MndrRlJlbFA2ajNBYlJKYUZEcUc2OVVzY0JGalFhTERzNlN0ZmxtT3pMNmpwS21vUVlXVDU0TDFDTGdyY0l1V3poSWt5d1lQNjVuaHVCTTZNZ0lid2daeTdYUzVCYlVEaC1EUjd1ZGUwLVRBeVR5Tm5XMy1wSU5jbnl3YmtuVGdXYVBESQ?oc=5","date":"2024-11-07","type":"deal","source":"Business Wire","summary":"Huons Accelerates Biopharmaceutical Development with Human-Derived Hyaluronidase - Acquires Stake in PanGen to Expand Bio-Pharma Business - Business Wire","headline":"Huons Accelerates Biopharmaceutical Development with Human-Derived Hyaluronidase - Acquires Stake in PanGen to Expand Bi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNai14RUQ4VVRDMmc2cTRtTUs4bXpDUHR4T1NoUWs0R09jYlpnVThsd1JmcTE3cUxuTUp6V1NHVGY3MmJjSkZOWFVKb09randLUFFyT1IwVEFmUnlzVS12SGFmTVkwaFpJRm0tZ3U5S2J0b0NoQVg0clltZTVsY0tJNjlUc3Z1SUZkVm9jWGlCTkRzV2FwSExXai13OEFlTjRJNHl5Q2ZPd0lnM0R5UWZ3Njl5OWh4M2lLa0pfWFFablpJZnpkbFJMRWc3dVNOWFllVmFBQWF5RzBBYUYwVTRSYWd0NFBaZThfX2xrSldPLTU4T1U0MXc?oc=5","date":"2024-07-18","type":"deal","source":"lupin.com","summary":"Lupin and Huons Sign License and Supply Agreement for Commercialization of Cyclosporine Ophthalmic Nanoemulsionin Mexico - Lupin | Press Release - lupin.com","headline":"Lupin and Huons Sign License and Supply Agreement for Commercialization of Cyclosporine Ophthalmic Nanoemulsionin Mexico","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-07-18","type":"pipeline","source":"ET HealthWorld","summary":"Lupin inks pact with Huons to market Ophthalmic Nanoemulsion in Mexico - ET HealthWorld","headline":"Lupin inks pact with Huons to market Ophthalmic Nanoemulsion in Mexico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1xZFE2RENnd042OG9jSXpLYVhMNGR6UTRCSlA0Mm9xWjhtUDBfeF9iZTQ3ZWc2aWVyU3p0aS1VWVJ2QU94eV9Rc3pVWnpybkZoYm5hdkhpa3Q4ajdfcWZhdEZwRlcwdjVEbTFkdlhn?oc=5","date":"2023-06-19","type":"regulatory","source":"KED Global","summary":"Huons’ 2% lidocaine gets approval from FDA - KED Global","headline":"Huons’ 2% lidocaine gets approval from FDA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9DNFktajRZUWxIbEZiS1hFMVRrX1JhNkFlYVVGNTlsS0RNVUdYaG85OHRmMXZlaFNZUWFlUjF1SV9hZW5tR3JGSGdPVnBrekhhbXRVTFZxd0VJSTcxUFM2c2tzcElndzNxclNyT2pn?oc=5","date":"2023-02-28","type":"regulatory","source":"KED Global","summary":"S.Korea's Huons gets approval to supply anesthetics to Canada - KED Global","headline":"S.Korea's Huons gets approval to supply anesthetics to Canada","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPa0NfRmRwekp1YWhVTnNKLXFuU0c0aFN6TXNicDBmV3lOcEZ4NVRZWU8tMFhVTi00SG82ZlRpTmtkcjFEcVdySHg0QXgzNV93N21FYzU5TnIyYzk1NmlhUjF6VUtOTkE1dm5saVZYb0hIY3FHVHU5dnNfMWNtTzhmdlh1ZG4zZFZLZHc2d3RrMnUxX2NSZ3VfUGRRS0k5bnk0Zm90TG9nT3pZelFWRlFETFVaYW55RVJtZnBtQzJHNkZ1ZGg0aU1uVWtCczZvbE9KSE1qRmhKZmNZVkZK?oc=5","date":"2021-04-15","type":"deal","source":"Reuters","summary":"Second S.Korean deal to produce Russia's Sputnik V - Reuters","headline":"Second S.Korean deal to produce Russia's Sputnik V","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1oaG9wMy1ISkJCak05OElyU0tFdzhSXzJySE1BQXUwTmt3V1o0YkFBeFZkS2JBQU16TFVNVXozUmFrQlVpMmd3a2hxbUplcElZc1FoSk93ZUVCRW92eFFyNGxBclBnSUlyaTZQQ9IBcEFVX3lxTE9Od2k5bXhjVmtHbXI3Z283alZXZU5PRFRWdmV3WW9ZSXFqU1ZRTlpBUnJzaUNYajVYbk5VODFkY1FTeGpkWjBOZHRGU1RicHNISGZHM1JyTEIySzgyUjdTOWprdG1lN2FadGl4dWRkQU4?oc=5","date":"2020-08-25","type":"regulatory","source":"koreabiomed.com","summary":"Huons' eye drop wins Saudi’s regulatory nod - koreabiomed.com","headline":"Huons' eye drop wins Saudi’s regulatory nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5nUkVpQlNLOC1DMjQ1aUlMZnBIZUpGQkk2RkFRQllGUG9pdnZCVmF0ZUJHU2tEaGJzVHZuZFZaUUVzUnJOODBHZmQ3NXN5N2U5UmtRODQyZWhrNThUT3h1QXhQSW5DT3I3SmszWdIBcEFVX3lxTE5lcmtTQjVsZkYzdmxobXJvNG5EU2JkN09oZl8wN0hmRTdYLWh6a1lXY3dScGtPUmxoWVhXNUd5Zkc0M08xMnRZYjVGSWEwSHBpckliZS13MDR4dG9fLUhjMWNmaXNpRDNqX2k0bk1oVTY?oc=5","date":"2020-06-04","type":"trial","source":"koreabiomed.com","summary":"Huons’ dry eye drop scores German nod for clinical trial - koreabiomed.com","headline":"Huons’ dry eye drop scores German nod for clinical trial","sentiment":"neutral"}],"patents":[],"drugCount":19,"phaseCounts":{"phase_3":15,"phase_2":2,"phase_1":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}